OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Real-time Bid/Ask 04:56:29 2024-05-07 EDT | ||
| 5.73 EUR / 5.74 EUR | +0.44% |
|
| Current month | +0.18% | ||
| 1 month | +41.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 5.74 | +0.53% | 0 |
| 24-05-06 | 5.71 | -1.55% | 0 |
| 24-05-03 | 5.8 | -1.02% | 0 |
| 24-05-02 | 5.86 | +2.81% | 0 |
| 24-04-30 | 5.7 | -1.38% | 0 |
Delayed Quote Börse Stuttgart
Last update May 07, 2024 at 04:20 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | CL9B41 |
| ISIN | DE000CL9B417 |
| Date issued | 2020-04-07 |
| Strike | 7,174 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.32 € |
|---|---|
| Lowest since issue | 0.54 € |
| Spread | 0.01 € |
| Spread % | 0.17% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
163.6
USD
Spread / Average Target
+8.19%
- Stock Market
- Certificates
- Certificat